Supplementary material
Appendix B, annex 1 (Table)

Table 1. General characteristics of of the sample according to CURB-65.

	CURB-65 <1 (n=94)	CURB-65 ≥2 (n=151)	*p*
Age (m, SD, years)	54 ± 14.6	64 ± 13	< 0.001
Male sex (n, %)	59 (63%)	114 (76%)	0.033
Personal history (n,%)			
Hypertension	34 (36.2%)	86 (57%)	0.002
Diabetes mellitus	22 (23.4%)	46 (30.5%)	0.23
Overweight/Obesity	19 (20.2%)	51 (34%)	0.02
Smoker	3 (3.2%)	12 (7.9%)	0.131
Ex-smoker	6 (6.4%)	16 (10.6%)	0.262
Heart disease	0 (0%)	11 (7.3%)	0.007
Ictus	3 (3.2%)	4 (2.6%)	0.804
COPD	3 (3.2%)	6 (4%)	0.752
Chronic kidney disease	2 (2,1%)	9 (6%)	0.159
Cancer	1 (1,1%)	4 (2.6%)	0.393
Usual treatment (n,%)			
ACEI	6 (6.5%)	20 (13.3%)	0.092
Angiotensin II receptor blockers	25 (26.6%)	55 (36.4%)	0.111
Metformin	19 (20.2%)	30 (20%)	0.968
Insuline	1 (1.1%)	13 (8.6%)	0.013
Clinical manifestations (n,%)			
COVID contact (+)	28 (30%)	36 (24%)	0.317
Days from symptom onset	8.39 ± 4.3	8.25 ± 4.46	0.807
Fever	78 (83%)	133 (88%)	0.261
Fatigue	69 (73.4%)	131 (86.8%)	0.009
Cough	83 (89.2%)	125 (82.5%)	0.167
Shortness of breath	86 (91.5%)	138 (91.4%)	0.979
Anosmia	7 (7.4%)	9 (6%)	0.647

Ageusia	5 (5.3%)	4 (2.6%)	0.28
Diarrhea	20 (21.3%)	39 (25.8%)	0.418
Nausea	5 (5.3%)	13 (8.6%)	0.337
Headache	33 (35.5%)	51 (33.8%)	0.785
Systolic blood pressure (m,SD)	126 ± 19	117 ± 23	0.005
Distolic blood pressure (m,SD)	76 ± 10	72 ± 14	0.013
Baseline oxygen saturation (m,SD)	88 ± 9	81 ± 15	< 0.001
Heart rate (m,SD)	97 ± 17	100 ± 19	0.241
Respiratory rate (m,SD)	25 ± 5	27 ± 6	0.002
Altered mental status	2 (2.1%)	30 (19.9%)	< 0.001
Skin rash	0 (0%)	3 (2%)	0.169
Crepitantes	64 (68.1%)	92 (60.9%)	0.257
Wheezing	9 (9.6%)	26 (16.6%)	0.124
Roncus	21 (22.3%)	55 (36.4%)	0.02
Edema in lower extremities	3 (3.2%)	7 (4,6%)	0.578
Blood test upon admission (n,%)			
Hemoglobin (m,SD,g/dL)	13.3 ± 1.5	13.2 ± 2.2	0.577
Leukocytes (m,SD,cells/mm^3)	11019 ± 6579	12298 ± 6230	0.127
Lymphocytes (m,SD,cells/mm^3)	1148 ± 856	1483 ± 2765	0.255
Platelets (m,SD,cells/mm^3)	291806 ± 140535	276250 ± 144525	0.419
C-reactive protein (m,SD,mg/L)	254 ± 330	290 ± 231	0.39
Ferritin (m,SD,ng/mL)	991 ± 635	1968 ± 2893	0.33
LDH (m,SD,UL)	453 ± 245	508 ± 251	0.158
D-dimer (m,SD,ng/mL)	1581 ± 1838	2596 ± 3366	0.091
Urea (m,SD,mg/dL)	42 ± 47	53 ± 37	0.069
Creatinine (m,SD,mg/dL)	0.92 ± 0.18	1.32 ± 0.69	0.059
GOT (m,SD,UI/L)	61 ± 57	75 ± 68	0.169
GPT (m,SD,UI/L)	62 ± 70	69 ± 99	0.621
Prothrombin time(m,SD,sec)	13.9 ± 2.5	14.9 ± 9.2	0,567
APTT (m,SD,seg)	32.2 ± 6.9	32.9 ± 7.6	0.633

Sodium (m,SD,mEq/L)	139 ± 5.2	138 ± 5.4	0.117
Potassium (m,SD,mEq/L)	4.3 ± 0.8	4.4 ± 1	0.805
IL-6 (m,SD,pg/mL)	95 ± 106	339 ± 726	0.187
Chest x-ray alterations (n=232, % in each group)			
Radiography without alterations	6 (6,9%)	2 (1.4%)	0.027
Unilobar pneumonia	8 (9%)	18 (12.6%)	0.398
Multilobar bilateral pneumonia	6 (6,7%)	15 (10.5%)	0.333
Bilateral pneumonia	67 (75.3%)	121 (84.6%)	0.078
Pleural effusion	7 (7.9%)	27 (18,9%)	0.021
Cardiomegaly	14 (15.7%)	22 (15.4%)	0.944
Chest CT alterations (n=157, % in each group)			
Ground-glass opacity	52 (94.5%)	93 (91.2%)	0.448
Involvement of patched	32 (58.2%)	61 (60.4%)	0.788
Bilateral involvement	49 (89.1%)	92 (90.2%)	0.827
Interstitial pattern	20 (37%)	67 (65.7%)	0.001
Microbiological tests (n,%)			
SARS-CoV-2 positive nasopharyngeal swab (n=54)	28 (51.9%)	26 (48.1%)	0.985
Nasopharyngeal swab positive for influenza A and B (n=74, 8 positives)	2 (2,7%)	6 (8.1%)	0.885
Pneumococcal antigenuria (n=73, 1 positive)	0 (0%)	1 (1.4%)	0.594
Prognostic variables (n,%)			
Admission to ICU	38 (41%)	79 (53%)	0.058
Days of admission in ICU (m,SD)	5 ± 9.2	6 ± 9.1	0.4
Total days of hospital stay (m,SD)	12.6 ± 11.3	12.2 ± 10.8	0.805
Required oxygen therapy	86 (91.5%)	128 (84.8%)	0.124
Required IMV	34 (36.2%)	83 (55%)	0.005
ARDS	46 (49.8%)	104 (68.9%)	0.002

Acute renal failure	9 (9.6%)	55 (36.4%)	<0.001
Septic shock	16 (17%)	53 (35.1%)	0.002
DIC	0 (0%)	4 (2.6%)	0.11
Hydroelectrolytic alterations	25 (26.6%)	42 (27.8%)	0.835
Ictus	2 (2.2%)	7 (4.6%)	0.317
Acute coronary syndrome	1 (1.1%)	5 (3.3%)	0.273
PE	1 (1.1%)	0 (0%)	0.203
DVT	0 (0%)	1 (0.7%)	0.43
Death	16 (17%)	86 (57%)	<0.001
Discharge at home	47 (50%)	36 (24%)	<0.001
Managed treatments (n,%)			
Hydroxychloroquine	62 (66%)	102 (68%)	0.797
Azithromycin	74 (78.7%)	116 (77%)	0.729
Lopinavir/Ritonavir	63 (67%)	102 (68%)	0.932
Oseltamivir	27 (29.7%)	32 (22%)	0.161
Tocilizumab	13 (14%)	49 (33%)	0.001
Nitazoxanide	13 (14%)	23 (15%)	0.741
Ivermectin	3 (3.2%)	4 (2.7%)	0.825
Prophylactic LMWH	48 (52%)	78 (52%)	0.911
Therapeutic LMWH	14 (15%)	45 (30%)	0.008
Corticosteroids	61 (64.9%)	98 (65.3%)	0.944
Days from onset of symptoms to start of treatment (m,SD)	8 ± 7.8	7.6 ±5	0.602
Duration of treatment (m,SD)	10 ± 7.6	8.8 ± 7	0.204

ACEI: Angiotensin-converting-enzyme inhibitors; APTT: activated partial thromboplastin time; ARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; CURB-65: Confusion, Urea > 42mg/dL, Respiratory rate > 30, Blood pressure < 90 mmHg (systolic) or < 60 mmHg (diastolic), 65 years old or older; GOT: glutamic oxaloacetic transaminase: GPT: glutamic pyruvic transaminase; DIC: disseminated intravascular coagulation; DVT: deep vein thrombosis; ICU: Intensive Care Unit; IL-6: interleukin 6; IMV: Invasive mechanical ventilation; LDH: Lactate dehydrogenase; LMWH: low-molecular-weight heparin prophylaxis dosing; NF: nasopharynx; PE: pulmonary thromboembolism; SD: standard deviation.

Figure 2. ROC curve to predict 30-day mortality of CURB-65 and qSOFA.